Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. The immune reaction during ischemia opens new doors for advanced targeted therapeutics. Nowadays stem cell therapy has shown better results in stroke-prone individuals. Few monoclonal antibodies like [[natalizumab]] have shown great impact on pre-clinical and clinical stroke trial studies ((Chavda V, Madhwani K, Chaurasia B. [[Stroke]] and [[Immunotherapy]]: Potential Mechanisms and its implications as immune-therapeutics. Eur J Neurosci. 2021 Apr 7. doi: 10.1111/ejn.15224. Epub ahead of print. PMID: 33829590.)). natalizumab.txt Last modified: 2024/06/07 02:49by 127.0.0.1